

**PLANNING & COMMISSIONING COMMITTEE
MEETING HELD ON 7 JUNE 2019
CHAIR'S UPDATE REPORT**

INTRODUCTION

This is the Chair's report to the Clinical Commissioning Group Board following the June 2019 Planning and Commissioning Committee.

STRATEGY

6.2 PRIMARY CARE PRESCRIBING REBATE OFFER

An overview of each scheme was detailed below:

Edoxaban (Lixiana)

Was a rebate scheme paid quarterly using Daiichi Sankyo's terms and conditions offering a further update to their existing arrangements with no thresholds or penalties.

- The term was until December 2022.
- There was a 12 month termination clause for both parties.
- The contract was legalistic but brief and understandable.
- There are restrictions on disclosure of the scheme details to NHS staff and under FOI but they appear practical and implementable. A redacted contract defines what was and was not confidential.

Beclometasone Dipropionate Inhaler(Clenil Modulite)

- Utilises PrescQIPP standard terms and conditions to deliver a quarterly rebate based on PACT usage alone.
- The rebate was paid within 30 days of receipt of an invoice from the commissioner.
- The term of the contract was 2 years from signing but the company has a 6 month termination clause making the effective term quite short at 6 months.
Approximate rebate value per 12 months was £33,124. based on the last 12 month prescribing of £220,832.

Discussion took place with regard to the number of rebates received and it was noted that work was taking place to proactively obtain alignment across the four Humber CCGs.

Concern was expressed in relation to whether the cost would influence prescribing. The Committee were assured that there was no clinical difference in drugs and

rebate decisions were not monetary driven. It was noted that PrescQIPP had reviewed both rebate schemes from a clinical cost effectiveness and contractual basis and concluded 'Scheme considered: No significant reservations'.

A vote occurred to endorse the rebates:

Beclometasone was approved.

Edoxaban (Lixiana) was voted on, 3 members approved, 3 objected and 1 abstained therefore the Chair had the casting vote, therefore the rebate was approved.

The Integrated Audit and Governance Committee (IAGC) meeting was taking place on 9 July 2019, whereby the Primary Care Prescribing Rebate Offer report would be submitted for approval.

6.4b Children, Young People and Maternity

Speech and Language Therapy (SLT) Service remains a priority for NHS Hull CCG. 2 bids will be presented to the Prioritisation panel on 21st June 2019, one for recurrent funding for the service and another for Hull City Council Children and Young People's Services to provide additional support to children waiting for initial speech and language therapy assessment or intervention.

The Strategic Outline Business case (Stage 1) for the Children's Integrated Health and Care Community Hub had been approved by the Hull City Council Informal Cabinet, CST and NHS Hull CCG Senior Leadership Team. The Transformation Board leading this work was reviewing the requirements for the more extensive next stage of the business case that was expected to be completed by April 2021.

The Community Paediatric Medical Service transferred to HUTH 1 April 2019. The service was undertaking a review of all children awaiting follow-up appointments as a backlog had been identified. The outcome and impact of this review was expected by September 2019.



Vincent Rawcliffe
Clinical Chair, Planning and Commissioning Committee
June 2019